secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001104659-23-089091
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics Q2 net loss $33.3M; cash $301M; CNTY-101 data expected by year end
--------------------------------------------------------------------------------

- Net loss of $33.3M for Q2 2023 vs $31.0M in Q2 2022; net cash used in operations $48.5M in H1 2023.
- Cash, equivalents, and investments $301.0M as of June 30, 2023; runway expected into 2026.
- Phase 1 ELiPSE-1 trial of CNTY-101 ongoing; initial data from Schedule A expected by year end 2023.
- Full year GAAP operating expense guidance $135M-$145M; includes $12M-$17M stock-based compensation.
- Recorded $4.2M impairment charge for consolidation of two leased facilities in Philadelphia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923089091/0001104659-23-089091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923089091/tm2322816d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer